Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC
Michael Trauner, Christopher L. Bowlus, Aliya Gulamhusein, Bilal Hameed, Stephen H. Caldwell, Mitchell L. Shiffman, Charles Landis, Andrew J. Muir, Andrew N. Billin, Jun Xu, Xiangyu Liu, Xiaomin Lu, Chuhan Chung, Robert P. Myers, Kris V. Kowdley
Topics & Concepts
MedicineInternal medicineInterquartile rangeFarnesoid X receptorUrsodeoxycholic acidGastroenterologyObeticholic acidHepatologyPrimary sclerosing cholangitisAutoimmune hepatitisAlkaline phosphataseBile acidHepatitisAgonistReceptorDiseaseChemistryBiochemistryNuclear receptorEnzymeGeneTranscription factorLiver Diseases and ImmunityInflammatory Bowel DiseaseCeliac Disease Research and Management